Passage Bio is a genetic medicines company based in Philadelphia, PA that is developing a deep pipeline of adeno-associated virus (AAV) delivered therapeutics for the treatment of rare monogenic central nervous system disorders (CNS).
We seek to deliver transformative therapies to patients by leveraging our team’s decades of experience, including our founders, as well as the transformative potential genetic medicine technology to develop treatments that improve outcomes for patients with serious, life-threatening, rare CNS disorders.
Critical to this strategy is what we believe to be a differentiated approach to genetic medicine development via our collaboration with Penn’s GTP and Orphan Disease Center, led by our co-founder and Chief Scientific Advisor Dr. James Wilson.
In addition to our strategy, we have recruited, beginning with our founders, Dr. Squinto, Dr. Wilson and Dr. Yamada, a world class team of leaders who have decades of experience in working in, creating and successfully growing rare disease, central nervous disorders and gene therapy focused companies.
We have assembled a deep pipeline of genetic medicine product candidates, including our three lead product candidates: PBGM01 for the treatment of GM1 gangliosidosis (GM1), PBFT02 for the treatment of frontotemporal dementia (FTD) and PBKR03 for the treatment of Krabbe disease.
Location: United States, Pennsylvania, Philadelphia
Employees: 51-200
Total raised: $226M
Founded date: 2018
Investors 5
Date | Name | Website |
- | Logos Capi... | logoscapit... |
- | Access Bio... | accessbio-... |
- | OrbiMed | orbimed.co... |
- | Frazier Li... | frazierls.... |
- | Vivo Capit... | vivocapita... |
Funding Rounds 2
Date | Series | Amount | Investors |
04.09.2019 | Series B | $110M | - |
14.02.2019 | Series A | $116M | - |
Mentions in press and media 11
Date | Title | Description | Source |
05.03.2024 | Passage Bio Seeks Pennsylvania College Student Candidates fo... | - | globenewsw... |
06.10.2021 | Passage Bio : Announces Pennsylvania Scholars Program to Hon... | October 6, 2021 Download(opens in new window) Philadelphia, PA - October 6, 2021 - Passage Bio, Inc.... | marketscre... |
09.03.2021 | How Covid-19 is changing rare diseases research | Twenty years after researchers published their first discoveries associated with human genome sequen... | medcitynew... |
27.09.2019 | NASH hopeful Genfit promotes Dean Hum to president; Im... | In 1999, while Dean Hum was an associate professor at Laval University in Quebec, Genfit re... | endpts.com... |
04.09.2019 | Passage Bio Closes $110 Million Series B Financing | PHILADELPHIA, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Passage Bio, a genetic medicines company developing... | citybizlis... |
04.09.2019 | Passage Bio Closes $110 Million Series B Financing | - | orbimed.co... |
04.09.2019 | Plotting clinical entry, James Wilson's gene therapy s... | James Wilson The gene therapy biotech that James Wilson helped found to take some rare disease ... | endpts.com... |
14.02.2019 | Passage Bio Founded With $116 million financing, led by Orbi... | - | orbimed.co... |
14.02.2019 | OrbiMed Advisors Leads $115.5M Series A for Passage Bio | PHILADELPHIA, Feb. 14, 2019 (GLOBE NEWSWIRE) -- Passage Bio today debuted with a $115.5 million Seri... | citybizlis... |
14.02.2019 | Passage Bio Launches with $115.5 Million Series A | PHILADELPHIA, Feb. 14, 2019 (GLOBE NEWSWIRE) -- Passage Bio today debuted with a $115.5 million Seri... | citybizlis... |
Show more